# Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

> **NCT02170571** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Insufficiency

## Interventions

- **DRUG:** Dabigatran etexilate

## Key facts

- **NCT ID:** NCT02170571
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2005-12
- **Final completion:** —
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02170571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02170571, "Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02170571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*